One example is the use of checkpoint inhibitors that recognize programmed death-ligand 1 (PD-L1) or cytotoxic T lymphocyte antigen 4 (CTLA-4) ligands on the cell membrane of tumor cells and block the inhibition mediated by those checkpoint inhibitors that prevent T cells from killing cancer cells [52,53]. The gene discussed is CD274; the disease is cancer.